Rigel Pharmaceuticals Inc (RIGL) — Cash Flow-to-Debt Ratio
Rigel Pharmaceuticals Inc (RIGL) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of $2.73 Million could theoretically repay 0% of its total liabilities ($104.71 Million) in one year. See free cash flow generation of Rigel Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rigel Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Rigel Pharmaceuticals Inc across 27 annual periods. Also explore Rigel Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Rigel Pharmaceuticals Inc (1999–2025)
Year-by-year debt coverage analysis for Rigel Pharmaceuticals Inc. For market capitalisation and broader financial context, see Rigel Pharmaceuticals Inc (RIGL) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.62x | $75.66 Million | $122.11 Million | ▲ +216.3% |
| 2024 | 0.20x | $31.47 Million | $160.69 Million | ▲ +597.5% |
| 2023 | -0.04x | $-5.74 Million | $145.87 Million | ▲ +92.1% |
| 2022 | -0.50x | $-73.76 Million | $147.90 Million | ▼ -1262.0% |
| 2021 | 0.04x | $5.88 Million | $136.95 Million | ▲ +106.3% |
| 2020 | -0.68x | $-52.19 Million | $76.35 Million | ▼ -54.4% |
| 2019 | -0.44x | $-41.51 Million | $93.75 Million | ▲ +78.0% |
| 2018 | -2.01x | $-58.83 Million | $29.23 Million | ▲ +52.1% |
| 2017 | -4.20x | $-77.56 Million | $18.46 Million | ▼ -27.9% |
| 2016 | -3.28x | $-75.89 Million | $23.11 Million | ▼ -466.2% |
| 2015 | -0.58x | $-23.41 Million | $40.37 Million | ▲ +78.5% |
| 2014 | -2.69x | $-69.75 Million | $25.89 Million | ▲ +44.3% |
| 2013 | -4.83x | $-86.06 Million | $17.81 Million | ▼ -18.8% |
| 2012 | -4.07x | $-85.19 Million | $20.95 Million | ▼ -22.9% |
| 2011 | -3.31x | $-69.38 Million | $20.96 Million | ▼ -245.6% |
| 2010 | 2.27x | $46.74 Million | $20.56 Million | ▲ +168.3% |
| 2009 | -3.33x | $-102.78 Million | $30.88 Million | ▼ -27.6% |
| 2008 | -2.61x | $-103.52 Million | $39.69 Million | ▼ -67.9% |
| 2007 | -1.55x | $-52.21 Million | $33.61 Million | ▼ -12.8% |
| 2006 | -1.38x | $-35.84 Million | $26.01 Million | ▼ -53.1% |
| 2005 | -0.90x | $-35.17 Million | $39.08 Million | ▲ +37.4% |
| 2004 | -1.44x | $-38.15 Million | $26.52 Million | ▲ +31.0% |
| 2003 | -2.09x | $-32.44 Million | $15.55 Million | ▼ -14.2% |
| 2002 | -1.83x | $-34.53 Million | $18.90 Million | ▼ -100.1% |
| 2001 | -0.91x | $-15.98 Million | $17.51 Million | ▼ -20.1% |
| 2000 | -0.76x | $-11.59 Million | $15.25 Million | ▼ -59.2% |
| 1999 | -0.48x | $-7.83 Million | $16.41 Million | — |